About one in five women with breast cancer who receive chemotherapy gain at least 5 pounds, and on average gain nearly 7 pounds by six months after treatment ends.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review of RCTs could determine whether chemotherapy consistently causes weight gain across diverse populations and identify effect sizes, moderators, and potential confounders.
A systematic review and meta-analysis of all randomized controlled trials comparing weight change in breast cancer patients receiving adjuvant chemotherapy versus those receiving no chemotherapy or alternative treatments, with standardized measurements of weight, BMI, and body composition at baseline, end of treatment, and 6–12 months follow-up, including at least 10 trials with >500 total participants.
An RCT could determine whether chemotherapy directly causes weight gain by comparing weight change in patients randomized to receive chemotherapy versus a non-chemotherapy control group.
A double-blind, placebo-controlled RCT of 300 women with early-stage breast cancer, randomized to receive standard adjuvant chemotherapy (e.g., AC-T) or a saline placebo infusion with matched monitoring, measuring weight, fat mass (DXA), and energy expenditure at baseline, end of treatment, and 6 months, with stratification by age, BMI, and menopausal status.
A prospective cohort study could confirm whether chemotherapy exposure predicts weight gain over time while adjusting for confounders like physical activity and diet.
A multicenter prospective cohort of 500 breast cancer patients, tracked from diagnosis through 12 months, with monthly assessments of weight, dietary intake, physical activity (accelerometry), fatigue, and hormone levels, comparing those receiving chemotherapy to those undergoing surgery or radiation alone.
A case-control study could identify whether patients who gained >5 lb after chemotherapy differ in baseline thyroid function, activity levels, or hormonal profiles compared to those who did not.
A matched case-control study comparing 100 breast cancer patients who gained >5 lb after chemotherapy to 100 matched controls who gained <1 lb, assessing pre-treatment thyroid markers, SHBG, estradiol, and physical activity levels to identify predictive factors.
A cross-sectional study could estimate the prevalence of weight gain among breast cancer survivors who received chemotherapy, but cannot determine causality or directionality.
A national survey of 2,000 breast cancer survivors, stratified by treatment type, measuring current weight and recalling weight change during chemotherapy, adjusting for age, menopausal status, and time since treatment.